Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Deferred Revenue (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Current Deferred Revenue for 7 consecutive years, with $17.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 54.18% to $17.6 million in Q4 2025 year-over-year; TTM through Nov 2025 was $17.6 million, a 54.18% decrease, with the full-year FY2025 number at $17.6 million, down 54.18% from a year prior.
  • Current Deferred Revenue was $17.6 million for Q4 2025 at Nurix Therapeutics, down from $26.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $48.1 million in Q4 2023 to a low of $17.6 million in Q4 2025.
  • A 5-year average of $37.2 million and a median of $38.0 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 49.82% in 2024, then tumbled 54.18% in 2025.
  • Nurix Therapeutics' Current Deferred Revenue stood at $41.2 million in 2021, then fell by 8.68% to $37.6 million in 2022, then rose by 27.81% to $48.1 million in 2023, then fell by 20.24% to $38.4 million in 2024, then crashed by 54.18% to $17.6 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Current Deferred Revenue are $17.6 million (Q4 2025), $26.0 million (Q3 2025), and $27.4 million (Q2 2025).